Overview

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of QAX576 if patients with fistulizing Crohn's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Infliximab